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The main aim of this systematic review was to analyse and compare the clinical effi-
cacy and safety of metronidazole, vancomycin and fidaxomicin in the therapy of C. 
difficile infection. Methods: Systematic review and meta-analysis of the literature 
using Bayesian mixed treatment comparison. Results: Nine studies were included 
in the mixed-treatment comparison. Our meta-analysis showed that clinical cure 
was more likely with fidaxomicin compared to vancomycin and metronidazole, 
however the differences were not significant. (odds ratios [95% CI]: fidaxomicin 
vs. vancomycin 1.19 [0.82-1.66]; vancomycin vs. metronidazole 1.69 [0.93-2.82] and 
fidaxomicin vs. metronidazole 2.00 [0.99-3.66]). Fidaxomicin therapy was signifi-
cantly more efficacious than vancomycin and metronidazole in endpoints of recur-
rence (odds ratios [95% CI]: fidaxomicin vs. vancomycin 0.47 [0.33-0.65]; vancomycin 
vs. metronidazole 0.91 [0.44-1.69] and fidaxomicin vs. metronidazole 0.43 [0.19-0.85]) 
and sustained cure (odds ratios [95% CI]: fidaxomicin vs. vancomycin 1.77 [1.35-
2.28]; vancomycin vs. metronidazole 1.49 [0.92-2.30]; and fidaxomicin vs. metroni-
dazole 2.64 [1.50-4.35]. There was no significant difference between fidaxomicin, 
vancomycin and metronidazole in safety endpoints. ConClusions: Fidaxomicin 
was the most efficacious therapeutic alternative in lowering the rate of recurrent 
C. difficile infections.
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objeCtives: To conduct mixed treatment comparisons (MTC) to compare sime-
previr, a new generation NS3/4A protease inhibitor, with boceprevir and telaprevir 
(all in combination with PR) and with PR alone in treatment-naïve and treatment-
experienced genotype 1 HCV infected patients. These MTC results were used to 
inform the cost-effectiveness model for simeprevir and to prepare submissions to 
HTA agencies (including NICE). Methods: A Bayesian MTC based on a systematic 
literature review was conducted. Outcomes of interest included sustained virologic 
response (SVR) rates, incidence of anaemia and rash and discontinuation due to 
adverse events (AEs) rates. Networks were based on treatment-, dose- and duration-
specific nodes. Q80K-positive patients were excluded from simeprevir arms for the 
analysis of SVR rates in line with EMA label considerations for simeprevir. Subgroup 
analyses were conducted to investigate heterogeneity, based on METAVIR scores, 
sub-genotypes 1a/1b and prior response. Results: Simeprevir was associated with 
higher SVR rates than PR alone in both treatment-naive (OR [95%CrI]: 4.83 [3.50-
6.70]) and treatment-experienced patients (ORs: 9.02 [5.54-15.01]) for simeprevir 
12+PR 24/48 weeks and 8.73 [5.42-14.19] for simeprevir 12 +PR 48 weeks). Compared 
to telaprevir and boceprevir, SVR rates tended to be higher for simeprevir with 
odds-ratios ranging from 1.27 [0.81-2.00] to 2.61 [1.44-4.74] in treatment-naïve and 
from 1.04 [0.78-1.38] to 1.74 [0.84-3.61] in treatment-experienced patients. In terms 
of safety, the risks of anaemia and discontinuations due to AEs were lower for 
simeprevir compared to PR alone, telaprevir and boceprevir. The risk of rash was 
lower for simeprevir compared to telaprevir, and similar compared to PR alone and 
boceprevir. ConClusions: This MTC in genotype 1 HCV patients suggests a similar 
or better efficacy and a better tolerability profile for simeprevir compared to tel-
aprevir and boceprevir both in treatment-naïve and treatment-experienced patients.
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objeCtives: Widespread uncontrolled use of antibiotics contributes to the develop-
ment of microbial resistance. Study of antibiotic consumption by ATC / DDD method 
in terms of DDDs/1000 inhabitants / day (DID) is one of the ways to control the 
resistance development rate. Macrolide antibiotics are widely used for treatment 
of infectious diseases; therefore, their consumption needs control. Methods: Data 
on packed macrolides consumption in Ukraine, Russia and Kazakhstan, provided 
by analytical companies researching pharmaceutical market - “Pharmstandard” 
and IMS Health, has been used for the study. Results: Comparing the figures in 
Ukraine, Russia and Kazakhstan, the largest consumption (in DID) was observed in 
Russia, Ukraine was in the second place, Kazakhstan was in the third place, during 
2010-2012. However, the data were not significantly different; indices were 1.496, 
1.445 and 1.356 DID respectively in 2012. The analysis results showed that azithro-
mycin was leading as of consumption in DID in 2010-2012. Every year, the consump-
tion of this preparation increases. Compared to 2010, in 2012 the azithromycin DID 
consumption index increased for 21.4% and amounted to 0.7931 DID. This means 
that 5.8% of the population of Ukraine takes one course of azithromycin (5 days) 
during the year. Growth of azithromycin consumption is associated with its high 
efficacy. It is accumulated in most tissues and organs, it has the least side effects 
and provides high compliance; it is used in pediatric practice from an early age. 
Azithromycin consumption rate in Russia and Kazakhstan increases every year as 
well. Calculations showed that 2.12% of the population took a course of azithromy-
cin in Russia during 2012; in Kazakhstan, this index equaled 4.59%. ConClusions: 
The analysis showed that, macrolide antibiotics consumption level in Ukraine, 
Kazakhstan and Russia within the study period was comparable.
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Recently licensed quadrivalent influenza vaccines (QIVs) containing a strain from 
each B lineage should address these issues, but their impact still needs to be 
estimated. Our study assesses retrospectively what would have been the public 
health benefit of routinely vaccinating the US population with QIV instead of 
TIV. Methods: We developed a dynamic compartmental model able to account 
for interactions between influenza B lineages (natural or vaccine-induced). The 
model simulates influenza dynamics for the period 2000-2014, to account for the 
long-term impact of infection and vaccination. Age-structured population dynam-
ics, vaccine efficacy (VE) per strain, and weekly ramp-up of vaccination coverage 
are modelled. Sensitivity analyses were performed on VE, duration of immunity, 
levels of vaccine-induced cross-protection between B strains. Results: Assuming 
a cross-protection of 70% of the matched VE, the model predicts that QIV would 
have prevented on average 15% more B-lineages cases. Elderly people (65+yo) and 
young seniors (50-64yo) benefit the most from QIV with 21% and 18% reduction 
of B cases respectively in those age groups. Reducing the cross-protection esti-
mate of the matched VE to 50%, 30%, and 0% improves the relative benefit of QIV 
to 25%, 30%, and 34% fewer B cases in the US. ConClusions: Using a realistic 
retrospective framework, with real-life vaccine mismatch, our analysis shows 
that routine vaccination with QIV has the potential to substantially reduce the 
number of influenza infections, even with relatively conservative estimates of 
TIV induced cross-protection.
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objeCtives: Human Papillomavirus (HPV) is the primum movens both in the eti-
opathogenesis of invasive cervical cancer and in other neoplastic malignant and 
benign lesions. HPV vaccination was implemented in Italy since 2008. The aim of 
this study is to evaluate the burden of HPV-related diseases and the effect of cur-
rent HPV-vaccination strategy in Italy. Methods: A multistate morbidity mortality 
model was developed in order to estimate the infection process on a theoretical 
cohort of Italian women. The conceptual Markov process was adapted considering 
the data available in national and international literature. 7 states (Health, Genital 
Warts, Grade 1 and Grade 2/3 cervical intraepithelial neoplasia, Cervical Cancer, 
Death for Cervical Cancer and death for other cause) and 18 transition probabili-
ties were considered. A 5-years incidence rate class was extrapolated and Rogers 
and Ledent method transformation was used to convert rates into probabilities. 
Vaccination efficacy was carried out by literature modelling review and based to 
the coverage rate of the two anti-HPV vaccines available in Italy. Life expectancy 
(ex), Quality Adjusted Life Years (QALYs), Disability Adjusted Life Years (DALYs) and 
Attributable risk (AR) were estimated for no intervention and vaccination strategies 
scenarios. Results: The preliminary results show that for a theoretical cohort of 
100,000 Italian women the e0 is equal to 84.31 years. With the present HPV vac-
cination strategy the e0 increase to 84.36 (+0.05) years. However, considering the 
HPV-related diseases altogether, the QALYs increase from 83.9 for no intervention 
to 84.1 for Vaccine prevention approach (+0.2QALYs). DALYs decrease of 0.6 thanks 
to Vaccination (2 DALYs for no intervention cohort vs 1.4 DALYs lived for vaccinated 
cohort). AR is equal to 0.08 and 0.29 for population and not vaccinated respec-
tively. ConClusions: The model demonstrates that, if we consider different HPV-
related diseases, Italian HPV vaccination strategy has significantly effect on health 
gains for female population.
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objeCtives: To evaluate the efficacy and safety of ceftriaxone and levofloxacin 
in treating community-acquired pneumonia and provide references for clinical 
application. Methods: This was a systematic review. Data were collected from 
literature (randomized controlled trails) published from January 2003 to January 
2014 through searching databases both at home and abroad, such as CNKI, 
WanFang Data, VIP, PubMed, Science Direct, Springer, Ovid, Wiley-Blackwell and 
The Cochrane Library (Issue1, 2014). Both qualitative analysis and quantitative 
analysis were conducted. Quantitative analysis (meta-analysis) was performed 
by RevMan 5.2. Results: Nine studies were included, involving 2233 patients. Of 
these, six studies (553 patients) met meta-analysis criteria. The results of meta-
analysis were clinical effective rates (RR= 0.90, 95%CI, P= 0.002), and adverse events 
rates (RR= 0.70, 95%CI, P= 0.22). The result of qualitative description as follows: 
one prospective, randomized study showed success rate were 89% in the ceftri-
axone group and 96% in the levofloxacin group; one multicenter retrospective 
study showed the mortality of the two groups were 3.1% and 2.0%, the length of 
hospital stay (LOS) were 5.5±3.5 days and 4.8±2.9 days respectively, with no sig-
nificant difference found between groups; the other retrospective study showed 
ceftriaxone could shorten LOS since it had a trend toward earlier switch to oral 
therapy. ConClusions: In general, current evidence shows that the efficacy 
for the treatment of community-acquired pneumonia of levofloxacin is superior to 
ceftriaxone, there were no significant difference in the incidence of adverse reaction.
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objeCtives: C. difficile is the leading cause of antibiotic associated infectious noso-
comial diarrhoea. A limited number of new pharmaceutical products have been 
developed and registered in past decades for the treatment of C. difficile infection. 
